Development of exon-humanized mice to elucidate the mechanisms of COVID-19 infection
First written in FY2020. 2 of 3 entries say "Advanced", first in FY2021. Latest entry: 2026-04-22.
No other company in this theme has enough history to compare yet.
- 2026-04-22AdvancedStatutory disclosure document
「The patent granted this time covers a technology for producing exon-humanized mice in which only the exons of a mouse gene retain human base sequences, while the intron※1 retains the mouse base sequence.」
The company received a notice of allowance for a U.S. patent covering exon-humanized mouse technology, demonstrating specific intellectual-property progress supporting the development of contract production, sales, collaborative research, and preclinical testing applications. - FY2021AdvancedAnnual report
「The Company proceeded with developing mice in which the exon of the receptor required for infection with the novel coronavirus had been humanized, using its proprietary exon-humanized mouse technology for which an international patent application is pending. It also began providing contracted services for the production of exon-humanized mice.」
For exon-humanized mice intended to elucidate the mechanisms of COVID-19 infection, the Company continued development and also began providing contracted production services. - FY2020First statedAnnual report
「For the purpose of elucidating the mechanism of COVID-19 infection and disease onset, we began developing mice in which the exon of the receptor necessary for infection by the virus had been humanised, using our proprietary exon-humanised mouse technology.」
The Company newly began COVID-19 research using its proprietary exon-humanized mouse technology.